Paolo Ghia

Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22.

Chronic B cell malignancies and bone marrow microenvironment.

CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells.

CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes.

The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression.

Chronic lymphocytic leukaemia: a model for investigating potential new targets for the therapy of indolent lymphomas.

Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.

The characterization of chemokine production and chemokine receptor expression reveals possible functional cross-talks in AML blasts with monocytic differentiation.

IL-12 regulates an endothelial cell-lymphocyte network: effect on metalloproteinase-9 production.

Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly.

Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses.

The nature and origin of the B-chronic lymphocytic leukemia cell: a tentative model.

Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene.

Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid.

HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses.

Diagnostic criteria for monoclonal B-cell lymphocytosis.

Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia.

The origin of B-cell chronic lymphocytic leukemia.

IGHV gene insertions and deletions in chronic lymphocytic leukemia: "CLL-biased" deletions in a subset of cases with stereotyped receptors.

Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process.

Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations.

Chronic lymphocytic leukemia.

The normal counterpart to the chronic lymphocytic leukemia B cell.

A woman and her canary: a tale of chlamydiae and lymphomas.

Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis.

Overview of monoclonal B-cell lymphocytosis.

Age-dependent accumulation of monoclonal CD4+CD8+ double positive T lymphocytes in the peripheral blood of the elderly.

From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity.

Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy.

Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?

Evidence for the significant role of immunoglobulin light chains in antigen recognition and selection in chronic lymphocytic leukemia.

The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring.

Expression and function of toll like receptors in chronic lymphocytic leukaemia cells.

B-cell clones as early markers for chronic lymphocytic leukemia.

Introduction to Chronic Lymphocytic Leukemia Young Investigator's Meeting.

Monoclonal B lymphocytosis in the general population.

The microenvironment in mature B-cell malignancies: a target for new treatment strategies.

Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study.

A novel Rag2-/-gammac-/--xenograft model of human CLL.

MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27.

HS1 has a central role in the trafficking and homing of leukemic B cells.

ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients.

How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection.

CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it?

Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL).

Commentary: Comparison of current flow cytometry methods for monoclonal B cell lymphocytosis detection.

Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals.

Inherited genetic susceptibility to monoclonal B-cell lymphocytosis.

Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase.

In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.

Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models.

Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients.

Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases.

Another piece of the puzzle: is there a "nodal" monoclonal B-cell lymphocytosis?

General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL.

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.

Monoclonal B-cell lymphocytosis: right track or red herring?

KIBRA gene methylation is associated with unfavorable biological prognostic parameters in chronic lymphocytic leukemia.

Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors.

KAP1 regulates gene networks controlling mouse B-lymphoid cell differentiation and function.

Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results.

Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?

In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors.

A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?

Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia.

Targeting B-cell anergy in chronic lymphocytic leukemia.

MBL versus CLL: how important is the distinction?

Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL.

Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia.

Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis.

Antigen selection in B-cell lymphomas--tracing the evidence.

Monoclonal B cell lymphocytosis and "in situ" lymphoma.

Reprogramming cell death: BCL2 family inhibition in hematological malignancies.

IgG-switched CLL has a distinct immunogenetic signature from the common MD variant: ontogenetic implications.

Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding.

The microenvironment in lymphomas--dissecting the complex crosstalk between tumor cells and 'by-stander' cells.

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

Clonal B-cell lymphocytosis: a new member?

Heterogeneous functional effects of concomitant B cell receptor and TLR stimulation in chronic lymphocytic leukemia with mutated versus unmutated Ig genes.

The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors.

SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders.

Management of chronic lymphocytic leukemia.

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.

Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy.

Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution.

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.

Ibrutinib: better combined with other drugs?

Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation.

Targeting Hedgehog in haematological malignancies.

Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

A new life for rituximab?

Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study.

Similar epidemiological trends of pre-neoplastic precursors and their respective lymphoid malignancies in Taiwan.

Ibrutinib holds promise for patients with 17p deletion CLL.

Ibrutinib in the real world patient: many lights and some shades.

Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications.

Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification.

Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations.

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.

Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments.

Monoclonal B-cell lymphocytosis: Does the elderly patient need a specialistic approach?

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.